ALLMedicine™ Angioedema Center
Research & Reviews 3,425 results
https://doi.org/10.1007/s40265-021-01475-4 10.1002/rth2.12175 10.1016/j.jaci.2020.10.015 10.1111/all.14670 10.1056/NEJMoa1716995
Drugs Lee A
Mar 1st, 2021 - Berotralstat (ORLADEYO™) is an orally administered kallikrein inhibitor, which has been developed by BioCryst Pharmaceuticals for hereditary angioedema (HAE). The inhibition of kallikrein by berotralstat decreases the production of bradykinin, whi...
https://doi.org/10.1007/s40268-021-00337-4 10.1111/all.13384 10.1016/j.anai.2012.10.008 10.1016/j.jaip.2013.07.002 10.1016/j.amjmed.2005.09.064 10.1016/j.anai.2020.02.018 10.1186/1750-1172-9-99 10.1007/s12016-016-8555-6 10.1186/s13223-019-0376-8 10.1016/j.anai.2017.05.017 10.1007/s10865-007-9147-y 10.1074/jbc.M114.569061 10.1001/jama.2018.16773 10.1016/j.jval.2011.04.002 10.1002/sim.5442 10.1002/sim.3165 10.1056/NEJMoa0805538 10.1186/s13223-019-0328-3 10.1186/1471-2288-10-54 10.1016/S0895-4356(97)00049-8 10.1111/all.14416 10.1016/j.jaci.2019.12.626 10.1016/j.anai.2015.06.006 10.2500/aap.2014.35.3753 10.1016/j.anai.2018.09.186
Drugs in R&D; Mendivil J, Malmenäs M et. al.
Mar 1st, 2021 - Hereditary angioedema (HAE) with C1-esterase inhibitor (C1-INH) deficiency is a rare disease associated with painful, potentially fatal swelling episodes affecting subcutaneous or submucosal tissues. HAE attacks recur with unpredictable severity a...
https://doi.org/10.1111/all.14798
Allergy Doña I, Torres MJ
Feb 28th, 2021 - Hereditary angioedema (HAE) is a rare inherited chronic disease characterisedby unpredictable recurrent attacks of cutaneous and submucosal swelling potentially involving airways, frequently upper ones,and compromising patient's life. This implies...
https://doi.org/10.1016/j.pupt.2021.102004
Pulmonary Pharmacology & Therapeutics; Jentsch Matias de Oliveira JR, Amorim MA et. al.
Feb 21st, 2021 - Angiotensin-converting enzyme inhibitors (ACEis) may cause adverse airway events, such as cough and angioedema, due to a reduction in bradykinin breakdown and consequent activation of bradykinin type 2 receptor (B2 receptor). Recent studies have s...
https://doi.org/10.1016/j.anai.2021.02.010
Annals of Allergy, Asthma & Immunology : Official Publica... Hayes S, Farrell C et. al.
Feb 20th, 2021 - Recombinant human C1 esterase inhibitor (rhC1-INH) is indicated in the United States for the treatment of acute HAE attacks in adolescents and adults; it is also indicated in Europe for children aged 2 years and older. A need exists for further in...
Guidelines 19 results
https://doi.org/10.1111/all.13384
Allergy Maurer M, Magerl M et. al.
Jan 10th, 2018 - Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. I...
https://doi.org/10.1111/cea.12494
Clinical and Experimental Allergy : Journal of the Britis... Powell RJ, Leech SC et. al.
Feb 25th, 2015 - This guidance for the management of patients with chronic urticaria and angioedema has been prepared by the Standards of Care Committee of the British Society for Allergy and Clinical Immunology (BSACI). The guideline is based on evidence as well ...
https://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20and%20Parameters/Urticaria-2014.pdf
Bernstein, J.
Apr 30th, 2014 - Theworkgroup was formed by the JTFPP to develop a practiceparameter to address the diagnosis and treatment of urticaria withor without angioedema. The chair, Jonathan Bernstein, MD,invited workgroup members to participate in the parameterdevelopme.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100605
Academic Emergency Medicine : Official Journal of the Soc... Moellman JJ, Bernstein JA et. al.
Apr 15th, 2014 - Despite its relatively common occurrence and life-threatening potential, the management of angioedema in the emergency department (ED) is lacking in terms of a structured approach. It is paramount to distinguish the different etiologies of angioed...
https://doi.org/10.1016/j.jaci.2013.03.034
The Journal of Allergy and Clinical Immunology; Zuraw BL, Bernstein JA et. al.
Jun 3rd, 2013 - These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council ...
Drugs 423 results see all →
Clinicaltrials.gov 4,005 results
https://doi.org/10.1007/s40265-021-01475-4 10.1002/rth2.12175 10.1016/j.jaci.2020.10.015 10.1111/all.14670 10.1056/NEJMoa1716995
Drugs Lee A
Mar 1st, 2021 - Berotralstat (ORLADEYO™) is an orally administered kallikrein inhibitor, which has been developed by BioCryst Pharmaceuticals for hereditary angioedema (HAE). The inhibition of kallikrein by berotralstat decreases the production of bradykinin, whi...
https://doi.org/10.1007/s40268-021-00337-4 10.1111/all.13384 10.1016/j.anai.2012.10.008 10.1016/j.jaip.2013.07.002 10.1016/j.amjmed.2005.09.064 10.1016/j.anai.2020.02.018 10.1186/1750-1172-9-99 10.1007/s12016-016-8555-6 10.1186/s13223-019-0376-8 10.1016/j.anai.2017.05.017 10.1007/s10865-007-9147-y 10.1074/jbc.M114.569061 10.1001/jama.2018.16773 10.1016/j.jval.2011.04.002 10.1002/sim.5442 10.1002/sim.3165 10.1056/NEJMoa0805538 10.1186/s13223-019-0328-3 10.1186/1471-2288-10-54 10.1016/S0895-4356(97)00049-8 10.1111/all.14416 10.1016/j.jaci.2019.12.626 10.1016/j.anai.2015.06.006 10.2500/aap.2014.35.3753 10.1016/j.anai.2018.09.186
Drugs in R&D; Mendivil J, Malmenäs M et. al.
Mar 1st, 2021 - Hereditary angioedema (HAE) with C1-esterase inhibitor (C1-INH) deficiency is a rare disease associated with painful, potentially fatal swelling episodes affecting subcutaneous or submucosal tissues. HAE attacks recur with unpredictable severity a...
https://doi.org/10.1111/all.14798
Allergy Doña I, Torres MJ
Feb 28th, 2021 - Hereditary angioedema (HAE) is a rare inherited chronic disease characterisedby unpredictable recurrent attacks of cutaneous and submucosal swelling potentially involving airways, frequently upper ones,and compromising patient's life. This implies...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64b232a9-f4f4-4613-9442-b53b86189035
Feb 23rd, 2021 - Promethazine Hydrochloride Tablets are useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urt...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7834998b-2c53-4edc-97d9-508f7cc92f7c
Feb 23rd, 2021 - Promethazine hydrochloride tablets, USP are useful for: Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticarial and angi...
News 235 results
https://reference.staging.medscape.com/viewarticle/936716_3
Sep 7th, 2020 - Although anaphylaxis can occur without skin symptoms, cutaneous reactions are the most common clinical manifestations of an allergic reaction to a food or food additive. Peanuts remain the most common cause of severe food allergy symptoms and anap...
https://www.mdedge.com/fedprac/article/213630/hospital-medicine/recurrent-angiotensin-converting-enzyme-inhibitor-induced/page/0/1?channel=327
Dec 5th, 2019 - Discussion The standard therapy for ACEI-inducedangioedema continues to be airway management and discontinuation of medication. However, life-threatening progression of symptoms have led to the use of off-label therapies, including FFP and bradyki.
https://reference.medscape.com/viewarticle/907375
Jan 14th, 2019 - New Antimicrobials New tetracyclines and antimicrobials for influenza, malaria, onchocerciasis, smallpox, and more New Drugs in Oncology and Hematology Include a wide range of targeted therapies and first-in-class agents New Drugs in Immunology Ne...
https://www.medpagetoday.com/rheumatology/generalrheumatology/76622
Nov 30th, 2018 - Action Points Patients with type I or type II hereditary angioedema (HAE) suffer from regular, unpredictable and life-disrupting attacks, and patients are in need of better drugs to control this lifelong disabling condition. Patients whose HAE is ...
https://www.medpagetoday.com/rheumatology/generalrheumatology/76542
Nov 27th, 2018 - Prophylactic treatment with lanadelumab (Takhzyro) prevented hereditary angioedema attacks and led to a clinically-meaningful impact on quality of life, according to the pivotal HELP trial that led to recent FDA approval. The monoclonal antibody c...